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Activation of Proto-Oncogenes in Human
and Mouse Lung Tumors
by Steven H. Reynolds* and Marshall W. Anderson*
Lung cancer is a leading cause ofcancer-related deaths in several nations. Epidemiological studies have
indicated that 85% of all lung cancer deaths and 30% of all cancer deaths in the U.S. are associated with
tobacco smoking. Various chemicals in tobacco smoke are thought to react with DNA and to ultimately
yield heritable mutations. In an effort to understand the molecular mechanisms involved in lung tumor-
igenesis, we have analyzed proto-oncogene activation in a series ofhuman lung tumors from smokers and
spontaneously occurring and chemically induced lung tumors in mice. Approximately 86% ofthe human
lungtumorsand >90%ofthe mouse lungtumorswere foundtocontain activatedoncogenes. rasOncogenes
activated by point mutations were detected in many of the human lung adenocarcinomas and virtually
all ofthe mouse lung adenomas and adenocarcinomas. The mutation profiles ofthe activated K-ras genes
detected in the chemically induced mouse lung tumors suggest that the observed mutations result from
genotoxic effects of the chemicals. Comparison of the K-ras mutations observed in the human lung ad-
enocarcinomas with mutation profiles observed in the mouse lung tumors suggest that bulky hydrophobic
DNA adducts may be responsible for the majority of the mutations observed in the activated human K-
ras genes. Other data indicate that approximately 20% of human lung tumors contain potentially novel
transforming genes that may also be targets for mutagens in cigarette smoke.
Introduction
There are four major histologic types oflung cancer:
adenocarcinoma (representing 30%), squamous or epi-
dermoid carcinoma (representing 25%), large cell car-
cinoma (15%), and small cell carcinoma (25%), with un-
common types (such as bronchiolalveolar carcinoma and
bronchial carcinoids) and combined types making up the
remaining 5% (1). Adenocarcinoma, squamous carci-
noma, and large cell carcinoma are collectively referred
to as "nonsmall cell lung cancer."
Epidemiological studies have indicated that approx-
imately 85% of all lung cancer deaths in the U.S. are
associated with tobacco smoking (2,3). Tobacco smoke
contains more than 3800 chemicals (2,4), and approxi-
mately 50 of these chemicals have been shown to be
mutagenic (5,6) or carcinogenic (2). It is generally
thought that an initial step in lung tumorigenesis in
smokers involves the conversion of these chemicals to
electrophilic species that can react covalently with cel-
lular macromolecules such as DNA to yield promuta-
genic DNA adducts. Using32P-postlabelingtechniques,
it has been shown that cigarette smokers have higher
DNA adduct levels than nonsmokers, and many of the
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DNA adducts appear to be smoking specific (7,8). A
causal relationship between specific chemicals and lung
cancerhasnotbeenestablished, butalinearrelationship
has been established between the number ofcigarettes
smoked and lung cancer risk (9).
The process ofcell transformation is a multistep phe-
nomenon. Increasing evidence suggests that a small set
ofcellular genes appear to be targets for genetic alter-
ations that contribute to the neoplastic transformation
of cells. The development of neoplasia may, in many
cases, require changes in at least two classes ofcellular
genes: proto-oncogenes (10) and tumor-suppressor
genes (11). For example, both the activation ofras on-
cogenes and the inactivation of several tumor-suppres-
sor genes have been observed in the development of
human colon tumors (12) and human lung tumors (13-
15). The activation ofproto-oncogenes in chemically in-
duced rodent tumors has been studied in great detail.
Investigations in rodent models for chemical carcino-
genesis imply that certain types of oncogenes are ac-
tivatedby carcinogen treatment andthatthis activation
process is an early event in tumor induction (16-18).
Several studies have detected activated oncogenes in
chemically induced rodent lung tumors (17-20). Lung
tumors from smokers provide a unique opportunity to
investigate proto-oncogene activation in a chemical-as-
sociated human tumor type. The focus of this paper is
to compare and discuss the activation of proto-onco-
genes in human and rodent lung tumors with special
emphasis on ras oncogenes.REYNOLDS AND ANDERSON
Table 1. Transforming genes in human lung tumors.
DNA source Focus assay Tumorigenicity assaya Transforming gene
T24 cell lineb + 8/8 H-ras
NIH 3T3 cellsc or
normal human lung 1/8
Large cell carcinoma 31 + 8/8 K-ras
Adenocarcinoma 1 + NT K-ras
Adenocarcinoma 14 5/16 c-raf
Adenocarcinoma 27 3/8
Adenocarcinoma 32 + 11/12 K-ras
Adenocarcinoma 33 8/20 non-ras
Adenocarcinoma 36 5/8 K-ras
Adenocarcinoma 41 5/8 non-ras
Adenocarcinoma 43 NT 4/8 K-ras
Adenocarcinoma 46 NT 6/8 N-ras
Epidermoid carcinoma 3 1/8 H-ras
Squamous cell carcinoma 11 0/8
Squamous cell carcinoma 40 3/8 non-ras
Squamous cell carcinoma 81 NT 7/8 N-ras
aTumors/injection sites.
bPositive control DNA.
cNegative control DNA.
dNT, not tested.
Results
Detection of Transforming Genes in
Human Lung Tumors
We used two general oncogene detection techniques,
the NIH 3T3 focus assay and the NIH 3T3 cotransfec-
tion nude mouse tumorigenicity assay, to analyze proto-
oncogene activation in a series of primary human lung
tumors from smokers. Overall, 12 of 14 (86%) of the
primary human lung tumors from smokers scored as
positive in either the NIH 3T3 focus assay or the NIH
3T3 cotransfection nude mouse tumorigenicity assay
(Table 1). The sensitivity of the tumorigenicity assay
appeared to be much greaterthanthatofthe focus assay
for the detection of transforming genes in human lung
tumors (Table 1).
Southern blot analysis revealed that five activated K-
ras genes, one activated H-ras gene, and two activated
N-ras genes were present in eight of the foci or nude
mouse tumor DNAs analyzed. Activated K-ras genes
were detected in one large cell carcinoma and four ad-
enocarcinomas, activated H-ras was detected in one epi-
dermoid carcinoma, and activated N-ras was detected
in an adenocarcinoma and a squamous cell carcinoma
(Table 1). An activated raf gene was detected in one
Table 2. ras Gene mutations detected in human lung tumors.
Tumor type Numbera Oncogene Activating mutation
Large cell carcinoma 1 K-ras GGT TGT
Adenocarcinoma 9 K-ras GGT TGT
Adenocarcinoma 2 K-ras GGT GCT
Adenocarcinoma 1 K-ras GGT GTT
Adenocarcinoma 1 N-ras CAA CTA
Squamous cell carcinoma 1 N-ras GGT GAT
Epidermoid carcinoma 1 H-ras ?
aTotal number of tumors containing a particular mutation.
adenocarcinoma and transforming genes that did not
hybridize to probes specific for H-, K-, or N-ras, c-raf,
met, neu, c-myc, c-abl, or the epidermal growth factor
(EGF) receptor were detected in two adenocarcinomas
and one squamous cell carcinoma (Table 1).
Mechanisms of Activation of ras
Oncogenes in Human Lung Tumors
ras Genes are usually activated in vivo by point mu-
tations at codon 12, 13, 61, 117, or 146 (21-23). We
therefore used the polymerase chain reaction (PCR)
gene amplification technique to amplify specific ras ex-
ons and performed direct dideoxy DNA sequencing to
determine the position of activating mutations in the
transfected ras oncogenes. All of the K-ras oncogenes
in the foci or nude mouse tumor DNAs were found to
be activated by a G:T transversion at the first base of
codon 12 (GGT -) TGT) (Table 2). The same activating
G:T transversions were detected in the original lung
tumor DNAs when analyzed by PCR amplification and
direct dideoxy DNA sequencing or oligonucleotide mis-
match hybridization. The N-ras genes were found to be
activated by a A:T transversion at the second base of
codon 61 (CAA -- CTA) or by a G:A transition at the
second base of codon 12 (GGT -* GAT) (Table 2). The
H-ras oncogene detectedinepidermoid carcinoma3was
found to contain only the normal DNA sequences in all
four coding exons and therefore appears to be activated
by a novel mechanism. An additional 19 adenocarcino-
mas were analyzed for K-ras activation by PCR gene
amplification of exon 1 followed by mismatch hybridi-
zation to 19-mer oligonucleotide probes containing all
possible activating mutations at codon 12. Eight of 19
adenocarcinomas were found to contain point mutations
at codon 12(5 GGT -- TGT, 2 GGT -- GCT, 1 GGT
GTT) (Table 2).
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Table 3. Mutation spectrum in K-ras oncogenes detected in spontaneous and chemically induced mouse lung tumors.a
Codon 12 (GGT) Codon 13 (GGC) Codon 61 (CAA)
No. of tumors Mutations Mutations Mutations
Treatmentb with K-ras TGT GTT GAT CGT CGC CTA CGA CAT UN
Spontaneous 19 0 4 4 1 0 0 7 2 1
BP 14 8 1 4 0 0 0 0 0 1
DMBA 10 0 0 0 0 0 10 0 0 0
EC 10 0 1 0 0 0 7 2 0 0
MNU 15 0 0 15 0 0 0 0 0 0
NMK 11 0 1 8 0 0 0 2 0 0
DMN 10 0 0 7 0 0 0 3 0 0
TNM 4 0 0 4 0 0 0 0 0 0
BD 6 0 0 0 0 6 0 0 0 0
aData from Stowers et al. (17), You et al. (18), Belinsky et al. (19), Goodrow et al. (20), and unpublished observations.
bAbbreviations: BP,benzo[a]pyrene; DMBA,dimethylbenz[a]anthracene; EC, ethylcarbamate; MNU, methylnitrosourea; NMK4-(N-methyl-
N-nitrosamino)-1-(3-pyridyl)-1-butanone; DMN, dimethylnitrosamine; TNM, tetranitromethane; BD, 1,3-butadiene; UN, unidentified mutation.
ras Gene Activation in Spontaneous and
Chemically Induced Mouse Lung Tumors
A number ofrecent reports from our laboratory have
demonstrated K-ras gene activation in spontaneous or
chemically induced A/J mouse lung tumors (18,19) and
in chemically induced B6C3F1 mouse lung tumors
(17,20). The mouse lungtumors fromthese studies were
classified as adenomas or adenocarcinomas and were
morphologically similar to lungtumors ofthe same type
in humans (17-20). The K-ras gene activation data from
these studies are summarized in Table 3.
Discussion
Recent studies (14,24) have speculated that muta-
tional activation of the K-ras oncogene detected in hu-
man lung adenocarcinomas might be a direct effect of
one or more carcinogenic ingredients oftobacco smoke.
Rodenhuis et al. found that 15 of 45 (33%) of the ad-
enocarcinomas from smokers contained activated ras
genes, whereas 6 of 6 (100%) of the adenocarcinomas
from patients who had never smoked did not contain an
activated ras gene (14,24). Thus, carcinogens in tobacco
smokemightbe amajorcausative factorintheinduction
of the ras gene point mutations in human lung adeno-
carcinomas. Furthermore, the reproducible activation
of K-ras oncogenes in chemically induced lung tumors
from different strains of mice has made it possible to
correlate the activating mutations with the promuta-
genicadducts formed directly orby metabolic activation
of the carcinogen. The selectivity of mutations in the
K-ras oncogene observed in chemically induced A/J
mouse lung tumors, as compared to spontaneous tu-
mors, suggests that these carcinogens directly induced
point mutations in the K-ras proto-oncogene (Table 3)
(18,19).
The mutation profile of the activated ras genes de-
tected in this (Table 2) and other studies (14,15,24) re-
veals that G:T transversions are the most frequently
detected ras gene mutations in adenocarcinomas and
large cell carcinomas of the lung. The fact that G:T
transversions are alsothe mostfrequently detected mu-
tations in activated ras genes in benzo[a]pyrene-in-
duced mouse lung tumors (18) (Table 3) suggests that
mutagens in cigarette smoke that give rise to aromatic
or bulky hydrophobic DNA adducts might be respon-
sible foractivation ofthemajority ofras genesin human
large cell carcinomas and adenocarcinomas ofthe lung.
In fact, several reports have demonstrated the exis-
tence of large numbers ofbulky hydrophobic DNA ad-
ducts in lung tissue of smokers and that these adducts
persist for up to several years after the cessation of
smoking (7,8).
The high incidence of activated oncogenes in human
lung tumors from smokers and chemically induced
mouse lung tumors (Tables 1 and 3) indicates that on-
cogene activation is an integral step in the development
of certain types of tumors, especially in those types
related to chemical exposure. The detection of poten-
tially novel transforming genes in approximately 20%
ofhuman lung tumors from smokers (Table 1) suggests
that genes other than H-, K-, or N-ras are putative
subtrates for mutagenic activation by carcinogens in
tobacco smoke.
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